Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C13H17N · HCl
CAS Number:
Molecular Weight:
223.74
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI key
IYETZZCWLLUHIJ-UTONKHPSSA-N
SMILES string
Cl[H].C[C@H](Cc1ccccc1)N(C)CC#C
InChI
1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1
grade
pharmaceutical primary standard
API family
selegiline
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... MAOB(4129)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Selective MAO-B inhibitor; anti-Parkinsonian agent.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral - STOT SE 3
target_organs
Central nervous system
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
监管及禁止进口产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Keiko Inaba-Hasegawa et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(3), 435-444 (2012-09-13)
Type B monoamine oxidase (MAO-B) is proposed to be involved in the pathogenesis of neurodegenerative disorders, such as Parkinson's disease, through oxidative stress and synthesis of neurotoxins. MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in
Rameshwar Singh et al.
Indian journal of experimental biology, 50(2), 101-109 (2012-06-08)
L-deprenyl is considered to protect against age-related cognitive deficits by improving long-term learning/memory in the aged brain. The CA1 and CA3 hippocampal areas are the sites at which initial learning and memory processes occur. Chronic deprenyl treatment significantly augmented the
Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
T Keränen et al.
International journal of clinical practice, 66(10), 1014-1014 (2012-09-22)
Wakako Maruyama et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(1), 83-89 (2012-08-16)
Neuroprotection has been proposed in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, to delay or halt disease progression or reverse neuronal deterioration. The inhibitors of type B monoamine oxidase (MAO), rasagiline and (-)deprenyl, prevent neuronal loss in cellular and
Chitra Sridar et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(12), 2256-2266 (2012-09-01)
Selegiline, the R-enantiomer of deprenyl, is used in the treatment of Parkinson's disease. Bupropion, an antidepressant, often used to treat patients in conjunction with selegiline, is metabolized primarily by CYP2B6. The effect of selegiline on the enzymatic activity of human
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service